UK parliamentarians have again discussed how to get Vertex’s cystic Fibrosis drug Orkambi (ivacaftor/lumacaftor) to patients as talks between NHS England and the company stagger on with no conclusion. Seema Kennedy, the parliamentary under-secretary for health and social care, said the government would now start looking at all options on the table, including a compulsory license.
Compulsory License On Table In UK For Orkambi
The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.
More from Europe
More from Geography
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
• By
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
• By
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.